Literature DB >> 11850105

Mitochondrial dysfunction in acute hyperammonemia.

Vicente Felipo1, Roger F Butterworth.   

Abstract

Acute hyperammonemia resulting from congenital urea cycle disorders, Reye syndrome or acute liver failure results in severe neuronal dysfunction, seizures and death. Increasing evidence suggests that acute hyperammonemia results in alterations of mitochondrial and cellular energy function resulting from ammonia-induced inhibition of the tricarboxylic acid cycle enzyme alpha-ketoglutarate dehydrogenase and by activation of the NMDA receptor. Antagonists of this receptor and NOS inhibitors prevent acute ammonia-induced seizures and mortality and prevent acute ammonia-induced changes in mitochondrial calcium homeostasis and cellular energy metabolism. Acute hyperammonemia also results in decreased activities of free radical scavenging enzymes and again, free radical formation due to ammonia exposure is prevented by either NMDA receptor antagonists or NOS inhibitors. Acute hyperammonemia also results in activation of "peripheral-type" benzodiazepine receptors and monoamine oxidase-B, enzymes which are localized on the mitochondrial membranes of astrocytes in the CNS. Activation of these receptors results in mitochondrial swelling and in increased degradation of monoamines, respectively. Alterations of mitochondrial function could contribute to the neuronal dysfunction characteristic of acute hyperammonemic syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850105     DOI: 10.1016/s0197-0186(01)00119-x

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  16 in total

Review 1.  Advances in urea cycle neuroimaging: Proceedings from the 4th International Symposium on urea cycle disorders, Barcelona, Spain, September 2013.

Authors:  Ileana Pacheco-Colón; Stanley Fricke; John VanMeter; Andrea L Gropman
Journal:  Mol Genet Metab       Date:  2014-05-20       Impact factor: 4.797

Review 2.  Metal toxicity, liver disease and neurodegeneration.

Authors:  Roger F Butterworth
Journal:  Neurotox Res       Date:  2010-04-06       Impact factor: 3.911

Review 3.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

Review 4.  Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy.

Authors:  Saul W Brusilow; Raymond C Koehler; Richard J Traystman; Arthur J L Cooper
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  Hepatic encephalopathy: An approach to its multiple pathophysiological features.

Authors:  Juan Carlos Perazzo; Silvina Tallis; Amalia Delfante; Pablo Andrés Souto; Abraham Lemberg; Francisco Xavier Eizayaga; Salvador Romay
Journal:  World J Hepatol       Date:  2012-03-27

Review 6.  Neurological implications of urea cycle disorders.

Authors:  A L Gropman; M Summar; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-11-23       Impact factor: 4.982

Review 7.  Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Laura E Halpin; Stuart A Collins; Bryan K Yamamoto
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

8.  Region-specific causal mechanism in the effects of ammonia on cerebral glucose metabolism in the rat brain.

Authors:  Nobuyuki Maruoka; Tetsuhito Murata; Naoto Omata; Hironori Mitsuya; Yasushi Kiyono; Hidehiko Okazawa; Yuji Wada
Journal:  J Neural Transm (Vienna)       Date:  2012-11-04       Impact factor: 3.575

Review 9.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

10.  Plasma fibroblast growth factor-21 levels in patients with inborn errors of metabolism.

Authors:  Brian Kirmse; Juan Cabrerra-Luque; Omar Ayyub; Kristina Cusmano; Kimberly Chapman; Marshall Summar
Journal:  Mol Genet Metab Rep       Date:  2017-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.